Under the guidance of Shanghai Municipal Commission of Economy and Informatization, Shanghai Industrial Technology Innovation Promotion Association, together with Shanghai Industrial Safety Monitoring and Early Warning Research Center, has carried out research on the innovation index of hardcore technology enterprises and established an evaluation indicator system. In 2024, at the Shanghai Industrial Technology Innovation Conference themed “Building the Main Engine of Innovation and Seizing New Opportunities in the Future”, Shanghai Industrial Technology Innovation Promotion Association, together with Shanghai Association for Science and Technology, released the list of 2024 Top 100 Hardcore Technology Enterprises in Shanghai. Mabwell is honored to be on the list.

Hardcore technology represents the cutting-edge technology in the field of high technology and is the beacon for the future industrial development. The listed enterprises are concentrated in the “3+6” industrial system, with an average R&D expenditure of 810 million yuan, an average of 1454 high-value patents, and an average of 77 PCT patents, demonstrating strong innovation capabilities and fruitful innovation results.

Being selected for the list is a recognition of Mabwell's research and development strength, innovation ability, and industry competitiveness. As an innovative biopharmaceutical company with a full industry chain layout, Mabwell is committed to providing patients with more effective and accessible biologic innovative drugs through original innovation.